EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease

Akira Matsumori

European Cardiology Review · 07.06.2023 · 18

DOI: 10.15420/ecr.2023.10 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 07.06.2023. Verfasst von Akira Matsumori. Beteiligte Einrichtung: Clinical Research Institute, National Hospital Organization, Kyoto Medical Center Kyoto, Japan. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is responsible for the regulation of genes involved in inflammation and immune responses. NF-κB may play an important role in cardiovascular diseases (CVDs), atherosclerosis and diabetes. Several therapeutic agents used for the treatment of CVDs and diabetes, such as pimobendan and sodium–glucose cotransporter 2 inhibitors, exert anti-inflammatory effects by inhibiting NF-κB activation; anti-inflammatory therapy may have beneficial effects in CVDs and diabetes. Several pharmacological agents and natural compounds may inhibit NF-κB, and these agents alone or in combination may be used to treat various inflammatory diseases. Immunoglobulin-free light chains could be surrogate biomarkers of NF-κB activation and may be useful for evaluating the efficacy of these agents. This review discusses recent advances in our understanding of how the NF-κB signalling pathway controls inflammation, metabolism and immunity, and how improved knowledge of these pathways may lead to better diagnostics and therapeutics for various human diseases.

Schlagwörter

Stichwörter der Autor:innen

Atherosclerosisbiomarkerdiabetesheart failureimmunoglobulin light chainsnuclear factor-κBsodium–glucose cotransporter 2 inhibitor

Autor:innen und Institutionen

  • Clinical Research Institute, National Hospital Organization, Kyoto Medical Center Kyoto, Japan.

Zitieren

APA

Matsumori, A. (2023). Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. European Cardiology Review, 18. https://doi.org/10.15420/ecr.2023.10

Vancouver

Matsumori A. Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. European Cardiology Review. 2023;18. doi:10.15420/ecr.2023.10

BibTeX
@article{Matsumori2023,
  author = {Matsumori, Akira},
  title = {Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease},
  journal = {European Cardiology Review},
  year = {2023},
  volume = {18},
  doi = {10.15420/ecr.2023.10}
}
Kostenlos starten →